These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25666253)

  • 21. [The current pharmacotherapy of pulmonary arterial hypertension].
    Betkier-Lipińska K; Ryczek R; Cwetsch A
    Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of calcium-channel blockers on right heart function in a controlled model of chronic pulmonary hypertension.
    Zierer A; Voeller RK; Melby SJ; Steendijk P; Moon MR
    Eur J Anaesthesiol; 2009 Mar; 26(3):253-9. PubMed ID: 19237986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pulmonary hypertension].
    Olschewski H; Ghofrani A; Wiedemann R; Rose F; Enke B; Gessler T; Voswinckel R; Kohstall M; Grimminger F; Seeger W
    Internist (Berl); 2002 Dec; 43(12):1498, 1501-9. PubMed ID: 12607389
    [No Abstract]   [Full Text] [Related]  

  • 25. Current medical treatment of pulmonary arterial hypertension.
    Sulica R; Poon M
    Mt Sinai J Med; 2004 Mar; 71(2):103-14. PubMed ID: 15029402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic treatment of pulmonary arterial hypertension.
    Ramani GV; Gill S
    Curr Pharm Des; 2013; 19(22):3963-73. PubMed ID: 23228314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of response to calcium channel blockers after long-term follow-up treatment in patients with idiopathic pulmonary arterial hypertension.
    Piloto B; Fernandes CJCDS; Jardim C; Castro M; Alves-Jr JL; Souza R
    J Bras Pneumol; 2023; 49(3):e20220337. PubMed ID: 37132695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium-channel blockers in pulmonary arterial hypertension.
    Chaumais MC; Macari EA; Sitbon O
    Handb Exp Pharmacol; 2013; 218():161-75. PubMed ID: 24092340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapies in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
    Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatments for pulmonary arterial hypertension.
    Liu C; Liu K; Ji Z; Liu G
    Respir Med; 2006 May; 100(5):765-74. PubMed ID: 16549344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of clinical characteristics and survival on patients with idiopathic pulmonary arterial hypertension and familial pulmonary arterial hypertension during conventional therapy era and targeted therapy era].
    Xu X; Sun M; Jiang X; Zhang R; Zhao Q; Wang Y; Sun K; Wang X; Peng F; Zheng L; Wen L; Jing Z
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jun; 42(6):465-8. PubMed ID: 25164218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasodilator therapy for primary pulmonary hypertension in children.
    Barst RJ; Maislin G; Fishman AP
    Circulation; 1999 Mar; 99(9):1197-208. PubMed ID: 10069788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of elderly hypertension with Ca channel blockers].
    Saito F; Kushiro T
    Clin Calcium; 2005 Oct; 15(10):1717-25. PubMed ID: 16199919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on current and emerging treatments for pulmonary arterial hypertension in childhood and adolescence.
    Wacker J; Weintraub R; Beghetti M
    Expert Rev Respir Med; 2019 Feb; 13(2):205-215. PubMed ID: 30614292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of dihydropyridinic calcium channel blockers in the management of hypertension.
    Coca A; Mazón P; Aranda P; Redón J; Divisón JA; Martínez J; Calvo C; Galcerán JM; Barrios V; Roca-Cusachs I Coll A
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):91-105. PubMed ID: 23259449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current treatment strategies for pulmonary arterial hypertension.
    Lee SH; Rubin LJ
    J Intern Med; 2005 Sep; 258(3):199-215. PubMed ID: 16115293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of calcium channel blockers in hypertension.
    Conlin PR; Williams GH
    Adv Intern Med; 1998; 43():533-62. PubMed ID: 9506192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary arterial hypertension: evaluation and management.
    LaRaia AV; Waxman AB
    South Med J; 2007 Apr; 100(4):393-9. PubMed ID: 17458400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium channel blockers in cardiovascular pharmacotherapy.
    Godfraind T
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):501-15. PubMed ID: 24872348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.